Unicycive Therapeutics, Inc. (UNCY) Income Statement
UNCY 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsUNCY revenue and net income
UNCY profit margins
UNCY growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
UNCY quarterly EPS vs estimates
Unicycive Therapeutics beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.33).
UNCY income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $675,000 | $951,000 | $0 | $0 | $0 | $0 |
| Cost of revenue | $572,000 | $428,000 | $284,000 | $7,000 | $1,000 | — | — | — |
| Gross profit | −$572,000 | −$428,000 | $675,000 | $951,000 | −$1,000 | — | — | — |
| Research & development | $9.1M | $20.0M | $12.9M | $12.4M | $6.1M | $1.0M | $795,000 | $344,000 |
| Sales, general & admin | $20.4M | $12.1M | $8.8M | $6.6M | $2.9M | $1.0M | $1.2M | $608,000 |
| Total operating expenses | $28.9M | $32.1M | $21.4M | $19.0M | $9.0M | $2.0M | $2.0M | $952,000 |
| Operating income | −$29.5M | −$32.1M | −$20.8M | −$18.1M | −$9.0M | −$2.0M | −$2.0M | −$952,000 |
| Interest income | $1.0M | $1.3M | $615,000 | $0 | — | — | — | — |
| Interest expense | $71,000 | $71,000 | $82,000 | $6,000 | $628,000 | $244,000 | $139,000 | $0 |
| Income before taxes | −$26.6M | −$36.7M | −$30.5M | −$18.1M | −$10.0M | −$2.3M | −$2.2M | −$1.1M |
| Income taxes | — | −$1.1M | $116,105 | $6,000 | $615,000 | $244,000 | $139,000 | −$952,000 |
| Net income | −$26.6M | −$36.7M | −$30.5M | −$18.1M | −$10.6M | −$2.5M | −$2.3M | −$1.1M |
| EBITDA | −$25.9M | −$36.2M | −$30.2M | −$17.9M | −$9.0M | −$2.0M | −$2.0M | — |
| EPS (diluted) | −$2.17 | −$4.85 | −$14.12 | −$8.85 | −$5.40 | −$1.64 | −$1.51 | — |
| Gross margin | — | — | 100.0% | 100.0% | — | — | — | — |
| Operating margin | — | — | −3,077.6% | −1,898.2% | — | — | — | — |
| Net margin | — | — | −4,525.0% | −1,899.5% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $568,000 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $211,000 | $151,000 | — | $138,000 | $135,000 | $284,000 | $123,000 | — | $284,000 | $82,000 | $79,000 |
| Gross profit | — | −$211,000 | −$151,000 | — | −$138,000 | −$135,000 | $284,000 | −$123,000 | — | −$284,000 | −$353,000 | −$79,000 |
| Research & development | $2.8M | $1.6M | $2.2M | $3.0M | $1.8M | $2.2M | $5.3M | $3.0M | $4.9M | $6.8M | $4.2M | $3.4M |
| Sales, general & admin | $7.4M | $6.8M | $5.0M | $4.4M | $5.2M | $5.8M | $4.0M | $3.2M | $2.5M | $2.4M | $2.2M | $2.6M |
| Total operating expenses | $10.1M | $8.2M | $7.2M | $7.3M | $7.0M | $8.0M | $9.3M | $6.3M | $7.4M | $8.9M | $6.3M | $5.9M |
| Operating income | −$10.1M | −$8.4M | −$7.2M | −$7.3M | −$7.0M | −$8.0M | −$9.3M | −$6.3M | −$7.4M | −$9.2M | −$6.3M | −$5.9M |
| Interest income | $441,000 | $394,000 | $351,000 | $279,000 | $155,000 | $226,000 | $314,000 | $416,000 | $462,000 | $69,000 | $140,000 | $227,000 |
| Interest expense | $0 | $0 | $27,000 | $15,000 | $13,000 | $15,000 | $20,000 | $15,000 | $16,000 | $20,000 | $19,000 | $18,000 |
| Income before taxes | −$1.7M | −$12.8M | −$14.7M | −$6.0M | −$6.4M | $570,000 | −$21.5M | −$4.1M | $9.9M | −$21.0M | −$7.8M | −$4.3M |
| Income taxes | — | — | — | — | — | — | −$240,724 | — | $5.9M | $240,724 | −$10.5M | −$79,000 |
| Net income | −$1.7M | −$12.8M | −$14.7M | −$6.0M | −$6.4M | $570,000 | −$21.5M | −$4.1M | $9.9M | −$21.0M | −$7.8M | −$4.3M |
| EBITDA | −$1.6M | −$12.6M | −$14.5M | −$5.8M | −$6.3M | $720,000 | −$21.5M | −$4.0M | $9.9M | −$20.7M | −$7.8M | −$4.2M |
| EPS (diluted) | −$0.06 | −$0.54 | −$0.82 | −$0.33 | −$0.52 | −$0.50 | $0.25 | −$0.50 | $1.50 | −$6.10 | −$0.22 | −$1.30 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −1,630.5% | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | −3,789.6% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in UNCY's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
UNCY financial results
Unicycive Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $26.6 million. Diluted earnings per share came to −$2.17.
See the UNCY stock overview for the latest quote and news, or the UNCY chart for price history and technical indicators.
UNCY income statement FAQ
Does Unicycive Therapeutics have revenue?
Unicycive Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Unicycive Therapeutics profitable?
No. Unicycive Therapeutics reported a net loss of $26.6 million in fiscal 2025.
How much does Unicycive Therapeutics spend on research and development?
Unicycive Therapeutics spent $9.1 million on research and development in fiscal 2025.
What are Unicycive Therapeutics's earnings per share?
Unicycive Therapeutics earned $-2.17 per diluted share in fiscal 2025, compared with $-4.85 a year earlier.
When will Unicycive Therapeutics report its next earnings?
Unicycive Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Unicycive Therapeutics's fiscal year end?
Unicycive Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.